# Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

> **NCT02683746** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 308 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Lyophilized albiglutide DCC pen injector
- **DRUG:** Lyophilized albiglutide DCC pen injector matching placebo
- **DRUG:** Albiglutide liquid auto-injector
- **DRUG:** Albiglutide liquid auto-injector matching placebo

## Key facts

- **NCT ID:** NCT02683746
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-16
- **Primary completion:** 2017-04-03
- **Final completion:** 2017-05-15
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02683746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02683746, "Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02683746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*